Current treatment strategies with lenalidomide in multiple myeloma and future perspectives
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current treatment strategies with lenalidomide in multiple myeloma and future perspectives
Authors
Keywords
-
Journal
Future Oncology
Volume 8, Issue 10, Pages 1223-1238
Publisher
Future Medicine Ltd
Online
2012-11-06
DOI
10.2217/fon.12.124
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IMWG consensus on maintenance therapy in multiple myeloma
- (2012) H. Ludwig et al. BLOOD
- A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
- (2012) M. A. Dimopoulos et al. BLOOD
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
- (2012) S. Lentzsch et al. BLOOD
- A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
- (2012) J R Berenson et al. LEUKEMIA
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
- (2011) T. E. Witzig et al. ANNALS OF ONCOLOGY
- Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial
- (2011) A. J. Jakubowiak et al. BLOOD
- Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
- (2011) P. M. Fayers et al. BLOOD
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
- (2011) A. Palumbo et al. BLOOD
- Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
- (2011) M.-V. Mateos et al. BLOOD
- Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide
- (2011) A. Larocca et al. BLOOD
- Management of older patients with multiple myeloma
- (2011) Francesca Gay et al. BLOOD REVIEWS
- Treatment Options for Relapsed and Refractory Multiple Myeloma
- (2011) Sagar Lonial et al. CLINICAL CANCER RESEARCH
- Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
- (2011) F Cavallo et al. LEUKEMIA
- Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents
- (2011) B Mohty et al. LEUKEMIA
- Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
- (2011) M A Dimopoulos et al. LEUKEMIA
- Immunomodulating Drugs in Myelodysplastic Syndromes
- (2011) L. Ades et al. Hematology-American Society of Hematology Education Program
- Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma
- (2010) Francesca Gay et al. AMERICAN JOURNAL OF HEMATOLOGY
- Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
- (2010) J. A. Zonder et al. BLOOD
- The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy
- (2010) A. K. Hsu et al. BLOOD
- The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
- (2010) Meletios Dimopoulos et al. CANCER
- Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program
- (2010) Evelien Kneppers et al. Clinical Lymphoma Myeloma & Leukemia
- Lenalidomide in multiple myeloma: current role and future directions
- (2010) Jerome B Zeldis et al. EXPERT OPINION ON PHARMACOTHERAPY
- Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
- (2010) J.-L. Harousseau et al. HAEMATOLOGICA
- Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
- (2010) Maria-Victoria Mateos et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Risky business in myeloma
- (2009) S. Lonial BLOOD
- Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
- (2009) S. Knop et al. BLOOD
- Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
- (2009) S. Kumar et al. BLOOD
- Treatment with deferasirox (Exjade®) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study
- (2009) Ersi Voskaridou et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
- (2009) Edward A. Stadtmauer et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
- (2009) H. Brenner et al. HAEMATOLOGICA
- Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
- (2009) Andrew Spencer et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
- (2009) M A Dimopoulos et al. LEUKEMIA
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
- (2009) R Fonseca et al. LEUKEMIA
- Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone
- (2008) Ulrike Klein et al. ANNALS OF HEMATOLOGY
- Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma
- (2008) Tomer Mark et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
- (2008) M. Wang et al. BLOOD
- Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- (2008) Peter H. Wiernik et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide in the treatment of multiple myeloma: a review
- (2008) X. Armoiry et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now